Document:

<PAGE>

                                     FORM OF
                                ROYALTY AGREEMENT

                  This Royalty Agreement (the "Agreement"), is made and entered
into as of ___________, 2000 (the "Effective Date"), by and between Cytomedix
GmbH, a Switzerland corporation ("Cytomedix"), and Curative Health Services,
Inc., a Minnesota corporation ("Curative").

                                    RECITALS

                  WHEREAS, Cytomedix and Curative are parties to that certain
Asset Purchase Agreement dated as of October 12, 2000 (the "Asset Purchase
Agreement"), pursuant to which Cytomedix and its Affiliates have agreed to
purchase certain assets of Curative and its Affiliates as set forth therein; and

                  WHEREAS, pursuant to Section 2.7(a)(viii) of the Asset
Purchase Agreement, it is a condition to the closing of the transactions
described in the Asset Purchase Agreement that the parties hereto enter into
this Agreement;

                                    AGREEMENT

                  NOW, THEREFORE, for and in consideration of the premises and
the mutual covenants contained herein, and for other good and valuable
consideration, the receipt, adequacy and legal sufficiency of which are hereby
acknowledged, the parties do hereby agree as follows:

                                   ARTICLE I.
                                  DEFINITI1ONS

                  For purposes of this Agreement, the following terms and
variations thereof have the meanings specified or referred to in this Article I:

                  "Affiliates" - any person or entity which directly or
indirectly controls, is controlled by, or is under common control with a party
hereto. For purposes of this Agreement, "control" means the legal, beneficial or
equitable ownership directly or indirectly of more than 50% of the aggregate of
all voting equity interests rights in such entity.

                  "Best Efforts" - the efforts that a prudent person desirous of
achieving a result would use in similar circumstances to ensure that such result
is achieved as expeditiously as possible; provided, however, that a person
required to use Best Efforts under this Agreement will not be required to
dispose of or make any change to its business, or expend any material funds or
incur any other material burden.

                  "FDA" - the United States Food & Drug Administration, or any
successor agency.

                  "Future Products" - any products developed and sold by
Cytomedix which embody any of the Patents or are covered by any claim of the
Patents.

                  "Net Sales Amount" - the invoiced amount of sales of Procuren
or the Future Products by Cytomedix or any of its affiliates or sublicensees to
third parties, less the following items: (a) customary trade, quantity and cash
discounts, sales rebates allowed and taken; (b) credits actually given for
rejected or returned products; (c) value-added, sales, use or turnover taxes,
excise taxes and customs

<PAGE>

duties included in the invoice amount; and (d) bad debt expense applied in a
manner that specifically relates to the Net Sales of the applicable product and
in accordance with GAAP.

                  "Patents" - the domestic and foreign patents being transferred
from Curative to Cytomedix pursuant to the Asset Purchase Agreement as set forth
on Schedule A, including any continuations-in-part, continuations, divisions,
substitutes, reissues, reexaminations or extensions thereof.

                  "Procuren" - Procuren(R), a thrombin-induced platelet
releasate.

                                   ARTICLE II.
                               ROYALTY OBLIGATIONS

                  Section 2.1 Amount of Payment. Cytomedix shall pay royalties
to Curative during the Term as set forth below:

                           (a) Cytomedix shall pay Curative three percent (3%)
                  of the aggregate Net Sales Amount of Procuren (such amount,
                  the "Procuren Royalty"), on a country by country basis, in
                  each of the countries listed on Schedule 2.1 (the "Applicable
                  Countries") for such time as any of the Patents with respect
                  to such Applicable Country remain valid, enforceable, and in
                  effect. Cytomedix shall have no further obligation to pay the
                  Procuren Royalty in any Applicable Country at such time when
                  no Patent with respect to such Applicable Country remains
                  valid, enforceable and in effect.

                           (b) Cytomedix shall pay Curative six percent (6%)
                  (the "Future Products Royalty Percentage") of the aggregate
                  Net Sales Amount of the Future Products (the "Future Products
                  Royalty," and together with the Procuren Royalty, the
                  "Royalty"), on a country by country basis, in each Applicable
                  Country for such time as any of the Patents with respect to
                  such Applicable Country remain valid, enforceable, and in
                  effect; provided, however, that at such time that the
                  aggregate worldwide Net Sales Amount of the Future Products
                  with respect to which the Future Products Royalty has been
                  paid since the Effective Date exceeds Three Hundred Million
                  Dollars ($300,000,000), the Future Products Royalty Percentage
                  shall thereafter be reduced to five percent (5%). Cytomedix
                  shall have no further obligation to pay the Future Products
                  Royalty in any Applicable Country at such time that no Patent
                  with respect to such Applicable Country remains valid,
                  enforceable and in effect.

                  Notwithstanding the foregoing, Cytomedix shall have no
obligation to pay any Royalties to Curative in connection with any sales of
Procuren made to Curative or any of its Affiliates pursuant to the terms of that
certain Supply Agreement of even date herewith, by and between Cytomedix and
Curative (the "Supply Agreement") until such time, if any, that Cytomedix
receives FDA approval of Procuren.

                  Section 2.2 Payment of Royalty. Cytomedix shall pay the
Royalty quarterly. Within forty-five (45) days after the end of each calendar
quarter, Cytomedix shall (a) pay Curative the amount of the Royalty owed by
Cytomedix for such calendar quarter, and (b) provide Curative with a written
report setting forth the Net Sales Amount with respect to Procuren and the
Future Products for the applicable quarter, and the computation of the Procuren
Royalty and the Future Products Royalty with respect thereto for the applicable
quarter. The Royalty shall be payable in currency of the United States of
America regardless of the country where earned and shall be paid or deposited as
designated in writing

                                       2

<PAGE>

by Curative. The exchange rate used to calculate the Royalty shall be the same
rate specified under Financial Accounting Standards Board Statement 52, or its
successor, used to translate the financial results of Cytomedix or its
Affiliates for public reporting. If the Royalty for the previous calendar
quarter remains unpaid within forty-five (45) days after the end of such
calendar quarter, interest shall accrue on such unpaid amount at the lower of
(a) fifteen percent (15%) per annum, or (b) the highest rate permitted by law,
until paid.

                  Section 2.3 No Other Compensation. Except as expressly
provided herein, Curative is not entitled to any other compensation from
Cytomedix or any other third party in connection with the sale of Procuren and
the Future Products and shall receive no royalty on sales of any other product
of Cytomedix.

                  Section 2.4 Records and Reports; Audits. Cytomedix shall keep
true and accurate records and books of account containing information necessary
for the determination of the Royalty payable hereunder. These records and books
of account shall upon reasonable notice be available during business hours for
inspection by Curative. Curative shall be entitled to conduct an audit, upon
thirty (30) days' prior written notice to Cytomedix, of such books and records.
Curative may engage an independent third party auditor to conduct such audits.
Cytomedix shall be entitled to receive a copy of any audit reports produced by
or on behalf of Curative hereunder. In the event any such audit reveals a
greater than five percent (5%) discrepancy between the correct amount of the
Royalty which should have been paid by Cytomedix pursuant to the terms herein
during the period covered by such audit and the actual amount of the Royalty
paid by Cytomedix during such period, Cytomedix shall reimburse Curative for the
costs of such audit.

                  Section 2.5 Milestones. Cytomedix covenants that it shall:

                           (a) submit a request to the FDA for a pre-IND
                  (Investigational New Drug) application meeting for Procuren
                  within three (3) months of the Closing Date;

                           (b) initiate a clinical trial for Procuren within 180
                  days of the release of any Institutional Review Board, or
                  State or Federal agency clinical holds subsequent to filing
                  the IND;

                           (c) submit a Biologics License Application (BLA) for
                  Procuren to FDA within twelve (12) months of completing a
                  successful Phase III clinical trial;

                           (d) make reasonable efforts to commercialize Procuren
                  in the United States within four (4) months of receiving final
                  FDA approval of the BLA; and

                           (e) upon termination of that certain
                  Commercialization Agreement dated as of January 19, 1998 (the
                  "BTG Agreement"), by and between Curative and BTG USA Inc., a
                  Delaware corporation, and successful completion of the
                  transfer of all data gathered under the BTG Agreement to
                  Cytomedix, Cytomedix will use reasonable efforts to initiate
                  pre-clinical animal studies to determine the feasibility of
                  using platelet factor 4 derived peptides to promote wound
                  healing.

                  Section 2.6 Offset. Notwithstanding any other provision in
this Agreement or the Asset Purchase Agreement, upon notice to Curative,
Cytomedix may set off any amounts owed by Cytomedix to the University of
Minnesota or any successor in interest pursuant to that certain Second Curatech
University of Minnesota Research Agreement dated as of September 30, 1988
against any

                                       3

<PAGE>

amounts otherwise payable to Curative under this Agreement; provided, however,
that the amount of such set-off shall not reduce (a) the Procuren Royalty
Percentage (after taking into account such set-off) below one and one-half
percent (1.5%) for any payment period, and (b) the Future Products Royalty
Percentage (after taking into account such set-off) below four and one-half
percent (4.5%) for any payment period, or, in the event the Future Products
Royalty Percentage has been reduced to five percent (5%) as set forth in Section
2.1(b) above, below three and one-half percent (3.5%) for any payment period.
The exercise of such right of set-off by Cytomedix in good faith, whether or not
ultimately determined to be justified, will not constitute an event of default
under this Agreement.

                                  ARTICLE III.
                                TERM; TERMINATION

                  Section 3.1 Term. This Agreement commences upon the Effective
Date and terminates at such time when Cytomedix has no further obligation to pay
any Royalties pursuant to Section 2.1 (the "Term").

                  Section 3.2 Termination. Upon thirty (30) days' prior written
notice to Curative, Cytomedix may terminate this Agreement if Curative breaches
any of its material obligations hereunder pursuant to Section 5.2 and fails to
cure such breach by the end of such thirty (30) day period, or, if the parties
agree that the breach is not capable of being cured or remedied within thirty
(30) days, then within a timeframe mutually agreed upon by the parties.

                  Section 3.3 Remedies upon Termination. Termination of this
Agreement shall not limit either party from pursuing any other remedies
otherwise available to it, including, without limitation, injunctive relief.

                  Section 3.4 Effect of Termination. In the event of notice of
termination, each party shall continue to perform its obligations hereunder up
to the date of termination. Upon termination, except as otherwise provided
herein, the obligations of the parties hereunder shall cease and Cytomedix shall
pay Curative any amounts then owing hereunder; provided however, that in the
event of termination due to a breach by Curative of Section 5.2, Cytomedix shall
have no right to offset any payment due to Curative under Section 2.1.

                                   ARTICLE IV.
                                 CONFIDENTIALITY

                  Each party acknowledges that any information concerning the
other party received in connection with this Agreement shall be deemed
"Confidential and Proprietary Information" (provided that information contained
within the Assets (as defined in the Asset Purchase Agreement) transferred to
Cytomedix shall not be deemed Confidential and Proprietary Information of
Curative). Each party agrees that it shall not permit the duplication, use or
disclosure of any such Confidential and Proprietary Information to any person or
entity (other than its own employees or agents who must have such information
for any proper purpose), unless (a) authorized in writing and signed by the
other party, or (b) legally required to disclose such information, provided that
the party availing itself of this exception has promptly notified the other
party of such required disclosure and has used commercially reasonable efforts
to lawfully avoid or limit such disclosure. Confidential and Proprietary
Information does not include any information which, at the time of disclosure,
is generally known by the public through no breach of the disclosing party. The
provisions of this Article IV shall survive the expiration or termination of
this Agreement.

                                       4

<PAGE>

                                   ARTICLE V.
                              INTELLECTUAL PROPERTY

                  Section 5.1 Right to Defend. At the election and expense of
Cytomedix, Cytomedix shall have the sole right (but not the obligation, except
as otherwise set forth in Section 5.3 below) to protect all intellectual
property rights related to Procuren and the Future Products, by obtaining and
maintaining appropriate patent, trademark, trade secret or other rights.
Curative agrees to cooperate, at the expense of Cytomedix, in the filing and
prosecution of patent applications in the United States and in foreign countries
in connection with all such intellectual property rights, and to promptly notify
Cytomedix of any conflicting uses of, or any applications or registrations to
use, any mark, name, symbol, device or word that becomes known to Curative that
Curative believes may constitute an act of infringement with respect to the
intellectual property rights related to Procuren and the Future Products.

                  Section 5.2 Ownership of Intellectual Property. Curative
acknowledges that, subject to Article VI, neither this Agreement nor the
performance of its obligations hereunder shall affect the ownership by Cytomedix
of any of the goodwill or intellectual property rights related to Procuren or
the Future Products, and such goodwill or other rights shall be and remain in
the name of Cytomedix. Curative warrants that, subject to Article VI, it shall
not at any time (a) do or cause to be done any act or thing contesting or in any
way impairing or tending to impair any part of such ownership and/or rights, or
(b) represent that it has any ownership in Procuren or the Future Products or
any intellectual property rights in connection therewith.

                  Section 5.3 Enforceability of Patents. Cytomedix shall use its
Best Efforts to ensure that the Patents remain valid and enforceable.

                                   ARTICLE VI.
                                SECURITY INTEREST

                  Section 6.1 Security Interest. Subject to the applicable terms
and conditions of this Agreement, Cytomedix hereby assigns and grants to
Curative a security interest (the "Security Interest") in and a lien on the
Patents (the "Collateral") to secure the payment and the performance of the
following obligations (collectively, the "Obligations"):

                           (a) the payment of the Royalty; and

                           (b) all reasonable costs incurred by Curative to
                  obtain, preserve, perfect and enforce the provisions of this
                  Article VI and the Security Interest created hereby, collect
                  the Royalty and maintain and preserve the Collateral,
                  including but not limited to taxes, assessments, insurance
                  premiums, repairs, reasonable attorney's fees and legal
                  expenses, and expenses of sale.

                  Section 6.2 Ownership of Collateral. Cytomedix shall defend
the Collateral against all claims and demands of all persons at any time
claiming any interest therein adverse to Curative which arises out of or relates
to any occurrence or event happening after the Closing (as defined in the Asset
Purchase Agreement) and Cytomedix shall keep the Collateral free from all liens
and security interests.

                  Section 6.3 Costs of Curative. Cytomedix shall pay all
reasonable costs necessary to obtain, preserve, perfect, defend and enforce the
Security Interest, collect the Obligations, and preserve, defend, enforce and
collect the Collateral, including but not limited to taxes, assessments,
insurance premiums, repairs, reasonable attorney's fees and legal expenses, and
expenses of sale. Without waiving

                                       5

<PAGE>

Cytomedix's default for failure to make any payment owed hereunder, Curative
may, at its option, pay any such costs and expenses and discharge encumbrances
on the Collateral, and such payment shall be part of the Obligations; provided,
that Curative shall not take any such action unless it has requested Cytomedix
to take such action in writing and Cytomedix has not taken such action within
thirty (30) days after its receipt of such request. Cytomedix shall reimburse
Curative on demand for any costs so incurred.

                  Section 6.4 Event of Default. The happening of any one or more
of the following listed events constituted an event of default (an "Event of
Default") by Cytomedix:

                           (a) Cytomedix fails to pay the Royalty owed hereunder
                  when due and does not cure such non-payment within ninety (90)
                  days of written notice thereof by Curative; or

                           (b) Cytomedix fails to meet the Milestones as set
                  forth in Section 2.5 .

                  Section 6.5 Remedies of Curative Upon Default. Remedies of
Curative Upon Default. Upon the occurrence of an Event of Default, Curative may,
upon giving fifteen (15) days written notice thereof to Cytomedix, Cytomedix
N.V., and Cytomedix, Inc., and after such parties have not cured such Events of
Default within the fifteen (15) day period, declare the Obligations in whole or
part immediately due and may enforce payment of the same and exercise any rights
under the Uniform Commercial Code as enacted in the State of New York, rights
and remedies under this Agreement, or otherwise. For purposes of this Section
6.5, to the extent the Event of Default is triggered by any failure to meet a
time deadline, such time deadline is to be treated as extended until the end of
such fifteen (15) day period for purposes of any cure. If Curative chooses to
exercise its rights to take possession and dispose of the Collateral in a
commercially reasonable manner, Cytomedix is still liable for any unpaid
Obligations and is entitled to any surplus in excess of the Obligations. If
Curative chooses to exercise its rights to take possession and retain the
Collateral in full satisfaction of the Obligations, Cytomedix is not liable for
any unpaid Obligations and is entitled to any surplus in excess of the
Obligations, such surplus as mutually determined by the parties in good faith.

                                  ARTICLE VII.
                                  MISCELLANEOUS

                  Section 7.1 No Joint Venture. Nothing herein shall create any
association, partnership, joint venture or agency relationship between the
parties hereto or any third party.

                  Section 7.2 Further Assurances. The parties shall cooperate
reasonably with each other in connection with any steps required to be taken as
part of their respective obligations under this Agreement, and the parties agree
(a) to furnish upon request to each other such further information, (b) to
execute and deliver to each other such other documents, and (c) to do such other
acts and things, all as the other party may reasonably request for the purpose
of carrying out the intent of this Agreement.

                  Section 7.3 Notices. All notices, consents, waivers, and other
communications under this Agreement must be in writing and are deemed to have
been duly given when (a) delivered by hand with written confirmation of receipt,
(b) sent by facsimile with confirmation of transmission by the transmitting
equipment, (c) five (5) days after delivery, if sent by certified mail, return
receipt requested, or (d) one (1) day after delivery, if sent by a nationally
recognized overnight delivery service, return receipt requested, in each case to
the appropriate addresses, or facsimile numbers set forth below (or to such
other addresses, facsimile numbers or as a party may designate by notice to the
other parties):

                                       6
<PAGE>

           Cytomedix:        Cytomedix GmbH
                             c/o Cytomedix, Inc.
                             Three Parkway North
                             Deerfield, Illinois 60015
                             Attention: Christopher J. Caywood
                             Vice President of Strategy and Business Development
                             Fax: (847) 405-7801

           with a copy to:   Latham & Watkins
                             1001 Pennsylvania Ave., N.W.
                             Suite 1300
                             Washington, D.C. 20004
                             Attention: Stuart S. Kurlander, Esq.
                             Fax: (202) 637-2201

           Curative:         Curative Health Services, Inc.
                             150 Motor Parkway
                             Hauppauge, New York 11788
                             Attention: William Tella
                             Sr. Vice President of Business Development
                             Fax: (631) 233-8107

           with a copy to:   Dorsey & Whitney LLP
                             250 Park Avenue
                             New York, New York 10177
                             Attention: Seth I. Truwit, Esq.
                             Fax: (212) 953-7201

                  Section 7.4 Waiver . The rights and remedies of the parties to
this Agreement are cumulative and not alternative. Neither the failure nor any
delay by any party in exercising any right under this Agreement operates as a
waiver of such right, and no single or partial exercise of any such right
precludes any other or further exercise of such right or the exercise of any
other right. To the maximum extent permitted by applicable law, (a) no claim or
right arising out of this Agreement can be discharged by one party, in whole or
in part, by a waiver or renunciation of the claim or right unless in writing
signed by the other party; (b) no waiver that may be given by a party is
applicable except in the specific instance for which it is given; and (c) no
notice to or demand on one party is deemed to be a waiver of any obligation of
such party or of the right of the party giving such notice or demand to take
further action without notice or demand as provided in this Agreement.

                  Section 7.5 Entire Agreement and Modification. This Agreement,
the Asset Purchase Agreement and the Supply Agreement constitute the entire
agreement between the parties with respect to the subject matter of this
Agreement and supersede all prior written and oral agreements and understandings
between the parties with respect to the subject matter of this Agreement. This
Agreement may not be amended except by a written agreement signed on behalf of
each of the parties hereto.

                  Section 7.6 Assignment. Except as set forth above, no party to
this Agreement may assign, transfer, or otherwise dispose of any of its rights,
duties, or obligations hereunder without the prior written consent of the other
party hereto; provided, however that upon prior written notice to the other
party, (a) either party may assign, transfer, or otherwise dispose of any of its
rights, duties or obligations hereunder to any of its Affiliates without the
consent of the other party (in which case the

                                       7
<PAGE>

assigning party shall continue to be liable for its obligations hereunder), and
(b) Curative may assign its right to receive the Royalty to any third party
without the consent of Cytomedix, provided that no such assignment or delegation
pursuant to clauses (a) or (b) shall relieve either party from any of its
obligations hereunder. Subject to the foregoing, this Agreement shall be binding
upon and shall inure to the benefit of the parties hereto and their permitted
successors and assigns.

                  Section 7.7 Severability. If any provision of this Agreement
is held invalid or unenforceable by any court of competent jurisdiction, the
other provisions of this Agreement remain in full force and effect. The parties
further agree that if any provision contained herein is, to any extent, held
invalid or unenforceable in any respect under the laws governing this Agreement,
they shall take any actions necessary to render the remaining provisions of this
Agreement valid and enforceable to the fullest extent permitted by law and, to
the extent necessary, shall amend or otherwise modify this Agreement to replace
any provision contained herein that is held invalid or unenforceable with a
valid and enforceable provision giving effect to the intent of the parties.

                  Section 7.8 No Third Party Beneficiary. No provision of this
Agreement shall create, or be deemed to create, any legal or equitable right in
any person not a party to this Agreement or give any such person any claim
against any party to this Agreement that such party would not have but for this
Agreement.

                  Section 7.9 Section Headings; Construction. The headings of
Articles and Sections in this Agreement are provided for convenience only and
will not affect its construction or interpretation. All words used in this
Agreement will be construed to be of such gender or number as the context
requires. The language used in the Agreement shall be construed, in all cases,
according to its fair meaning, and not for or against any party hereto. The
parties acknowledge that each party has reviewed this Agreement and that rules
of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be available in the interpretation of this
Agreement.

                  Section 7.10 Governing Law; Jurisdiction. This Agreement is to
be governed by and construed under the laws of the State of New York without
regard to conflicts of laws principles that would require the application of any
other law. The parties agree that the state and federal courts located in New
York County, New York shall be the sole venue and shall have sole jurisdiction
for the resolution of all disputes arising hereunder.

                  Section 7.11 Execution of Agreement, Counterparts. This
Agreement may be executed in one or more counterparts, each of which is deemed
to be an original copy of this Agreement and all of which, when taken together,
are deemed to constitute one and the same agreement. The exchange of copies of
this Agreement and of signature pages by facsimile transmission shall constitute
effective execution and delivery of this Agreement as to the parties and may be
used in lieu of the original Agreement for all purposes. Signatures of the
parties transmitted by facsimile are deemed to be their original signatures for
any purpose whatsoever.

                  [remainder of page intentionally left blank]

                                       8
<PAGE>

                      [signature page to Royalty Agreement]

                  IN WITNESS WHEREOF, the parties have executed this Agreement
as of the date first written above.

                                    CYTOMEDIX:
                                    CYTOMEDIX GMBH

                                    By:
                                       -----------------------------------------
                                    Name:
                                         ---------------------------------------
                                    Its:
                                        ----------------------------------------

                                    CURATIVE:
                                    CURATIVE HEALTH SERVICES, INC.

                                    By:
                                       -----------------------------------------
                                    Name:
                                         ---------------------------------------
                                    Its:
                                        ----------------------------------------

                                       9
<PAGE>

                                   SCHEDULE A

                                     PATENTS

[PATENTS TO BE TRANSFERRED UNDER THE ASSET PURCHASE AGREEMENT]

                                       10
<PAGE>

                                  SCHEDULE 2.1

                              APPLICABLE COUNTRIES

[COUNTRIES OF PATENTS TO BE TRANSFERRED UNDER ASSET PURCHASE AGREEMENT]

                                       11<PAGE>

                     FIRST AMENDMENT TO CONSULTING AGREEMENT

         This FIRST AMENDMENT TO CONSULTING AGREEMENT (the "First Amendment") is
made and entered into this 15th day of September, 2000, by and between
Cytomedix, Inc., a Delaware corporation (the "Company"), and BDR Consulting,
Inc., an Arkansas corporation ("BDR").

         WHEREAS, the Company's predecessor organization, Autologous Wound
Therapy, Inc. and BDR have previously entered into a "Consulting Agreement"
effective as of October 29, 1999, a copy of which is attached hereto as Schedule
1; and

         WHEREAS, the Company and BDR are desirous of amending the Consulting
Agreement as set forth herein.

         NOW, THEREFORE, in consideration of the mutual promises contained
herein, and of other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound, agree as follows:

SECTION 1.  AMENDMENT OF THE CONSULTING AGREEMENT.

In accordance with Section 9(b) of the Consulting Agreement, the parties agree
to amend the Consulting Agreement as follows:

a. Section 5, captioned, as "CONSULTING FEES." is hereby re-designated as
Section 5(a).

b. A new Section 5(b) is hereby added to Section 5, which reads:

         "(b) In further consideration for services to be provided hereunder by
         BDR, the Company grants BDR an option to purchase seventy-two thousand
         fifty-six shares of the Company's common stock at an exercise price of
         $7.69 per share."

c. Exhibit A, entitled "CONSULTING FEE SCHEDULE" is hereby amended by replacing
it with a new Exhibit A, which is attached to this First Amendment as Schedule 2

SECTION 2.  EFFECT OF AMENDMENT.

a. It is expressly understood by the parties that any shares acquired by BDR in
connection with the option described in this First Amendment shall be subject to
that certain Voting Agreement dated September 15, 2000 entered into by Jim D.
Swink, Jr., a principal of BDR; Cytomedix, NV; and David C. Demarest as
Proxyholder and shall be considered to be "After-Acquired Shares" as that term
is defined in Section 4 of the Voting Agreement.

b. It is further expressly understood by the parties that the option granted
under this this First Amendment shall not be considered a violation of Section
4.2 of the Voting Agreement.

<PAGE>

c. The option granted to BDR in this First Amendment shall otherwise be subject
to and governed by the applicable terms and conditions of the Voting Agreement
and the Company's Long Term Incentive Plan as adopted by the Company's Board of
Directors, approved by the Company's shareholders and otherwise in force and
effect as of the date of this First Amendment.

SECTION 3.  MISCELLANEOUS.

3.1      Entire Agreement.  This Agreement (including the Schedules 1 and 2
         attached hereto):

         3.1.1 constitutes the entire agreement among the parties hereto with
         respect to the subject matter hereof and supersedes all prior
         agreements and understandings, both written and oral, among the
         parties, or any of them, with respect to the subject matter hereof;

         3.1.2 shall not be assigned by operation of law or otherwise without
         the prior written consent of the party hereto purported to be affected
         by such assignment, or such person's estate or legal representative;
         and

         3.1.3 shall not be amended, waived, altered or modified in any manner
         whatsoever, except by a written instrument executed by the affected
         parties.

3.2      Counterparts. This Agreement may be executed in two or more
         counterparts for each respective Stockholder, each of which shall be
         deemed to be an original, but all of which shall constitute one and the
         same agreement.

3.3      Governing Law. This Agreement shall be governed by, construed, and
         enforced in accordance with, the applicable laws of the State of
         Delaware without giving effect to its principles or rules regarding
         conflicts of laws.

3.4      Notices. All notices and other communications to any party hereunder
         shall be in writing, duly signed by or on behalf of the party or
         parties giving it, shall be served by hand, first-class mail
         (registered or certified, return receipt requested), facsimile, or
         professional air courier:

         3.4.1    if to BDR, at the addressee as follows:

                  Jim D. Swink, Jr.
                  BDR Consulting, Inc.
                  10 Levant
                  Little Rock, Arkansas  72212

                  Telephone:  (501) 960-5550

                                       2
<PAGE>

         3.4.2    if to Cytomedix, to the addresses as follows:

                  Cytomedix, Inc.
                  Three Parkway North
                  Deerfield, Illinois 60015
                  Attention:  David C. Demarest, General Counsel

                  Telephone:  (847) 405-7813
                  Facsimile:  (847) 405-7801

         The parties may change their addresses and contact numbers from time to
time and such will become effective upon delivery of notice of such changes, in
accordance with the provisions of this Section 3.4.

3.5      Interpretation. The headings contained in this Agreement are for
         reference purposes only and shall not affect in any way the meaning or
         interpretation of this Agreement. Whenever the words "include,"
         "includes," and "including" are used in this Agreement, they shall be
         deemed to be followed by the words "without limitation".

3.6      Severability. Any term or provision of this Agreement which is held
         invalid or unenforceable in any jurisdiction shall, as to that
         jurisdiction, be ineffective to the extent of such invalidity or
         unenforceability without rendering invalid or unenforceable the
         remaining terms and provisions of this Agreement or affecting the
         validity or enforceability of any of the terms or provisions of this
         Agreement in any other jurisdiction. If any provision of this Agreement
         is so broad as to be unenforceable, the provision shall be interpreted
         to be only so broad as is enforceable.

3.7      Fees of Legal Counsel. In the event any party to this Agreement shall
         employ legal counsel with respect to any claim concerning the
         interpretation or any breach of this Agreement, or otherwise to protect
         its rights hereunder or to enforce any term or provision hereof, the
         prevailing party shall have the right to recover from the other party
         all of its reasonable attorneys' fees and out of pocket costs and
         expenses incurred in connection therewith.

3.8      Time for Performance.  Time is of the essence in this Agreement.

3.9      Further Assurances. Each Stockholder further agrees to execute all
         additional writings, consents and authorizations as may be reasonably
         requested by the parties to evidence the agreements herein.

                                       3

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.

         Cytomedix, Inc.                            BDR Consulting, Inc.

         -----------------------------              ---------------------------
         James A. Cour                                       Jim D. Swink, Jr.
         CEO                                                 President and CEO

                                       4
<PAGE>

                                   SCHEDULE 1

                              CONSULTING AGREEMENT

                               [copy as attached]

                                       5

<PAGE>

                                   SCHEDULE 2

                     EXHIBIT A AS AMENDED BY FIRST AMENDMENT

                               [copy as attached]

                                       6

<PAGE>

                                    EXHIBIT A

                             CONSULTING FEE SCHEDULE

         For purposes of this Agreement the consulting fees shall be based on
the rolling twelve month aggregate gross revenues of the Company measured as of
the close of the month immediately prior to the month for which the payment is
due is being calculated. For example, the payment due December 31, 2000, would
be based on the aggregate gross revenues for the rolling twelve month period
ending November 30, 2000. The fee due and payable shall be computed as follows:

            Rolling Annual Gross Revenues              Monthly Fee
            -----------------------------              -----------

              $0 to $7.5 Million                          $6,000

              $7.5 Million and above                     $10,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]